CY1124800T1 - Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου - Google Patents
Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτουInfo
- Publication number
- CY1124800T1 CY1124800T1 CY20211100878T CY211100878T CY1124800T1 CY 1124800 T1 CY1124800 T1 CY 1124800T1 CY 20211100878 T CY20211100878 T CY 20211100878T CY 211100878 T CY211100878 T CY 211100878T CY 1124800 T1 CY1124800 T1 CY 1124800T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pyrido
- pyrimidine derivative
- present
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 159000000016 pyrido[3,4-d]pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Ο σκοπός της παρούσας εφεύρεσης είναι να παρέχει ένωση που έχει εξαιρετική ανασταλτική δράση CDK4/6. Η παρούσα εφεύρεση είναι ένωση που αντιπροσωπεύεται από το γενικό τύπο (Ι) ή φαρμακευτικώς αποδεκτό άλας αυτής.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015110684 | 2015-05-29 | ||
| PCT/JP2016/065770 WO2016194831A1 (ja) | 2015-05-29 | 2016-05-27 | ピリド［３，４－ｄ］ピリミジン誘導体及びその薬学的に許容される塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124800T1 true CY1124800T1 (el) | 2022-11-25 |
Family
ID=57442335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100878T CY1124800T1 (el) | 2015-05-29 | 2021-10-08 | Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10124004B2 (el) |
| EP (1) | EP3305785B1 (el) |
| JP (1) | JP6400196B2 (el) |
| KR (1) | KR102601320B1 (el) |
| CN (1) | CN107614499B (el) |
| AR (1) | AR104789A1 (el) |
| AU (1) | AU2016272258B2 (el) |
| CA (1) | CA2987019C (el) |
| CL (1) | CL2017003032A1 (el) |
| CO (1) | CO2017012067A2 (el) |
| CY (1) | CY1124800T1 (el) |
| DK (1) | DK3305785T3 (el) |
| ES (1) | ES2893478T3 (el) |
| HK (1) | HK1249502A1 (el) |
| HR (1) | HRP20211360T1 (el) |
| HU (1) | HUE056996T2 (el) |
| IL (1) | IL255488B (el) |
| LT (1) | LT3305785T (el) |
| MX (1) | MX2017015277A (el) |
| MY (1) | MY192487A (el) |
| PH (1) | PH12017502171A1 (el) |
| PL (1) | PL3305785T3 (el) |
| PT (1) | PT3305785T (el) |
| RU (1) | RU2695337C2 (el) |
| SA (1) | SA517390409B1 (el) |
| SG (1) | SG11201709837RA (el) |
| SI (1) | SI3305785T1 (el) |
| TW (1) | TWI714590B (el) |
| WO (1) | WO2016194831A1 (el) |
| ZA (1) | ZA201707499B (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017364807B2 (en) | 2016-11-28 | 2021-05-13 | Teijin Limited | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
| US11261182B2 (en) * | 2016-11-28 | 2022-03-01 | Teijin Pharma Limited | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof |
| CN107337634B (zh) * | 2017-08-28 | 2019-07-09 | 新发药业有限公司 | 一种阿贝西利中间体化合物的制备方法 |
| AU2018354972B2 (en) | 2017-10-27 | 2021-07-08 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of ribociclib and its salts |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| EP3865488A4 (en) | 2018-12-19 | 2021-12-22 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | MACROCYCLIC COMPOUND AS CDK INHIBITOR, METHOD OF MANUFACTURING AND MEDICAL USE |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AR119493A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
| WO2022037592A1 (zh) * | 2020-08-17 | 2022-02-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物 |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| TW202320750A (zh) * | 2021-10-25 | 2023-06-01 | 香港商優領醫藥科技(香港)有限公司 | 含四氫呋喃多環類衍生物、其藥學上可接受的鹽及其製備方法和應用 |
| CN116410189B (zh) * | 2021-12-30 | 2024-08-06 | 中国科学院上海药物研究所 | 一种嘧啶并吡啶类化合物及其药用组合物和应用 |
| WO2023155841A1 (zh) * | 2022-02-16 | 2023-08-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物的盐型、晶型 |
| US20240092761A1 (en) * | 2022-07-18 | 2024-03-21 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| JP4053073B2 (ja) | 2003-07-11 | 2008-02-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 選択的ｃｄｋ４阻害剤のイセチオン酸塩 |
| CA2567569A1 (en) * | 2004-05-21 | 2006-01-26 | Banyu Pharmaceutical Co., Ltd. | Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton |
| GEP20135785B (en) | 2008-08-22 | 2013-03-11 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
-
2016
- 2016-05-27 KR KR1020177034478A patent/KR102601320B1/ko active IP Right Grant
- 2016-05-27 CA CA2987019A patent/CA2987019C/en active Active
- 2016-05-27 HU HUE16803266A patent/HUE056996T2/hu unknown
- 2016-05-27 PL PL16803266T patent/PL3305785T3/pl unknown
- 2016-05-27 CN CN201680033175.XA patent/CN107614499B/zh active Active
- 2016-05-27 DK DK16803266.2T patent/DK3305785T3/da active
- 2016-05-27 US US15/577,802 patent/US10124004B2/en active Active
- 2016-05-27 WO PCT/JP2016/065770 patent/WO2016194831A1/ja active Application Filing
- 2016-05-27 JP JP2017521910A patent/JP6400196B2/ja active Active
- 2016-05-27 SG SG11201709837RA patent/SG11201709837RA/en unknown
- 2016-05-27 ES ES16803266T patent/ES2893478T3/es active Active
- 2016-05-27 PT PT16803266T patent/PT3305785T/pt unknown
- 2016-05-27 MX MX2017015277A patent/MX2017015277A/es unknown
- 2016-05-27 EP EP16803266.2A patent/EP3305785B1/en active Active
- 2016-05-27 TW TW105116653A patent/TWI714590B/zh active
- 2016-05-27 AU AU2016272258A patent/AU2016272258B2/en active Active
- 2016-05-27 AR ARP160101534A patent/AR104789A1/es active IP Right Grant
- 2016-05-27 SI SI201631322T patent/SI3305785T1/sl unknown
- 2016-05-27 MY MYPI2017704377A patent/MY192487A/en unknown
- 2016-05-27 RU RU2017141454A patent/RU2695337C2/ru active
- 2016-05-27 LT LTEPPCT/JP2016/065770T patent/LT3305785T/lt unknown
-
2017
- 2017-11-06 ZA ZA2017/07499A patent/ZA201707499B/en unknown
- 2017-11-07 IL IL255488A patent/IL255488B/en active IP Right Grant
- 2017-11-25 SA SA517390409A patent/SA517390409B1/ar unknown
- 2017-11-28 CO CONC2017/0012067A patent/CO2017012067A2/es unknown
- 2017-11-29 PH PH12017502171A patent/PH12017502171A1/en unknown
- 2017-11-29 CL CL2017003032A patent/CL2017003032A1/es unknown
-
2018
- 2018-06-22 HK HK18108004.7A patent/HK1249502A1/zh unknown
-
2021
- 2021-08-26 HR HRP20211360TT patent/HRP20211360T1/hr unknown
- 2021-10-08 CY CY20211100878T patent/CY1124800T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124800T1 (el) | Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1123988T1 (el) | Ενωση πυριδινης | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
| EA201600128A1 (ru) | СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2(1Н)-ОНА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ И АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ | |
| UY35834A (es) | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| AU2015211852A1 (en) | Heterocyclic sulfonamide derivative and medicine comprising same | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| SA519401827B1 (ar) | [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه | |
| CY1125355T1 (el) | Πεντακυκλικη ενωση | |
| CY1122423T1 (el) | Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1 | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| ECSP19013196A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| DOP2015000299A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| EA201791743A1 (ru) | Производные имидазо[2,1-в]тиазола и 5,6-дигидроимидазо[2,1-в]тиазола, применяемые в качестве s100-ингибиторов | |
| CY1121709T1 (el) | Παραγωγο τετραϋδροπυρρολο[3,4-d][1,3]θειαζινης ως αναστολεας της bace | |
| PL408803A1 (pl) | Nowe 5-arylowe i 5-metylowe pochodne układu 1H-pirazolo[4,3-e][1,2,4,]triazolo[3,4-b][1,2,4]triazyny |